Market Share of Insulin Glargine Industry
The global insulin glargine market is moderately consolidated, mainly consisting of three major manufacturers (Sanofi, Novo Nordisk, and Eli Lilly) with a global market presence. The remaining manufacturers are confined to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (insulin glargine), whereas Biocon collaborated with Mylan to develop Semglee (an insulin glargine biosimilar). Prominent players, such as Sanofi, Novo Nordisk, and Lilly, have created a monopoly in the market through their established supply chains and branding, which has resulted in substantial market penetration. These companies work in tandem with several administrative and health agencies to deploy competitive strategies and restrict or eliminate competition from emerging market players.
Insulin Glargine Market Leaders
-
Sanofi Aventis
-
Novo Nordisk AS
-
Biocon
-
Eli Lilly and Company
-
Julphar
*Disclaimer: Major Players sorted in no particular order
